PolyPid Ltd. announced a corporate update on November 13, 2024, highlighting significant progress in its SHIELD II Phase 3 trial for D-PLEX100. The company confirmed that the last patient had been enrolled for the planned unblinded interim analysis.
The outcome of this unblinded interim analysis is expected later in the fourth quarter of 2024. Furthermore, PolyPid anticipates completing the full enrollment for the SHIELD II trial in December 2024.
Top-line results from the SHIELD II trial are projected to be reported in the first quarter of 2025. These timelines are critical for the continued development and potential regulatory submission of D-PLEX100.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.